“FDA-approved peptides” is one of the most-blurred phrases in this market: sellers borrow the halo of approved peptide drugs to legitimize research chemicals. The cure is a list. Here is what is actually approved, what is explicitly not, and the rule that connects them.
Approved peptide drugs (selection, 2026)
| Molecule | Brand(s) | Approved for |
|---|---|---|
| Semaglutide | Ozempic, Wegovy, Rybelsus | Type 2 diabetes; obesity |
| Tirzepatide | Mounjaro, Zepbound | Type 2 diabetes; obesity; OSA |
| Liraglutide | Victoza, Saxenda | Type 2 diabetes; obesity |
| Insulin analogs | Humalog, Lantus, and others | Diabetes |
| Tesamorelin | Egrifta / Egrifta WR | HIV-associated lipodystrophy |
| Bremelanotide (PT-141) | Vyleesi | HSDD in premenopausal women |
| Setmelanotide | Imcivree | Rare genetic obesity syndromes |
| Elamipretide (SS-31) | Forzinity (accelerated approval, Sept 2025) | Barth syndrome |
| Teriparatide | Forteo | Osteoporosis |
| Octreotide / lanreotide | Sandostatin, Somatuline | Acromegaly, neuroendocrine tumors |
| Leuprolide / goserelin | Lupron, Zoladex | Prostate cancer, endometriosis |
| Glucagon | GlucaGen, Gvoke | Severe hypoglycemia |
| Desmopressin, oxytocin, calcitonin… | various | Long-established peptide medicines |
The pattern worth noticing: peptides are a thriving, legitimate drug class. Approval is not rare or hostile territory for peptides; it is simply absent for the specific compounds the gray market sells.
Explicitly not approved (the ones people ask about)
| Compound | Actual status |
|---|---|
| BPC-157 | FDA Category 2; no compounding pathway |
| TB-500 / thymosin beta-4 | Never approved; WADA prohibited |
| Ipamorelin | FDA Category 2; development abandoned by pharma |
| CJC-1295 | Never approved |
| Sermorelin | Formerly approved (Geref), discontinued 2008; no current approved product |
| GHK-Cu (injectable) | Cosmetic use is a different lane; injectable never approved |
| Melanotan II | Never approved; multiple health-agency warnings |
| Epitalon, MOTS-c, KPV, Semax, Selank, Dihexa, AOD-9604, pinealon | Research chemicals; several reviewed by PCAC in 2026 with no status change |
| Retatrutide | Phase 3; the FDA states it cannot currently be legally compounded |
| Survodutide | Phase 3; same status as retatrutide |
| IGF-1 LR3 | Never approved (mecasermin, plain IGF-1, is approved for rare growth disorders) |
The rule that resolves every edge case
FDA approval attaches to a product (a manufactured drug, at a dose, for an indication), never to a molecule in the abstract. That is why bremelanotide is approved while PT-141 vials are not, why elamipretide's 2025 approval does not legitimize “SS-31 for longevity”, and why sermorelin's discontinued approval leaves it in a gray compounding lane rather than an approved one. When a seller says “FDA-approved peptide”, the only question that matters is: which product, for what?
The full legal framework, including the compounding categories and the 2026 policy signals, is in Are peptides legal in the US?
Frequently asked questions
What peptides are FDA approved?
Dozens of peptide drugs hold FDA approval, including insulin analogs, GLP-1s (semaglutide, tirzepatide, liraglutide), tesamorelin, bremelanotide, setmelanotide, teriparatide, octreotide, leuprolide, and, since September 2025, elamipretide. Approval always attaches to a specific product and indication, never to a molecule sold as a research chemical.
Is BPC-157 FDA approved?
No. BPC-157 has never been approved for anything, and the FDA placed it in Category 2 of its compounding review (significant safety concerns), which also blocks pharmacy compounding. Any site implying otherwise is misreading or misrepresenting the record.
Does FDA approval of a molecule make gray-market vials legal?
No. Approval covers a specific manufactured product for a specific indication. Bremelanotide being approved as Vyleesi does not legalize PT-141 research vials; semaglutide's approval does not legalize unlicensed copies. The product, not the molecule, carries the approval.